Atlas FDA

ETI-MAK-2 Plus Assay

FDA premarket approval P990038/S029 · decided 2019-07-18

Approval details

PMA number
P990038
Supplement
S029
Supplement type
30-Day Notice
Supplement reason
Process Change - Manufacturer/Sterilizer/Packager/Supplier
Trade name
ETI-MAK-2 Plus Assay
Generic name
Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen)
Applicant
DiaSorin, Inc.
Date received
2019-06-18
Decision date
2019-07-18
Days to decision
30 days
Decision code
OK30
Product code
LOM
Advisory committee
Microbiology
Expedited review
No
Location
Stillwater, MN
Statement
Relocation of reagent manufacture from one room to another within the same establishment

Class III intelligence, same tools

PMAs share the API, exports and alerts with 510(k) data - watch an applicant and hear about every approval.

510(k) clearances by this applicant

RecordFirmDate
LIAISON Murex HBsAg Qual; LIAISON XL; LIAISON diluteX (K260770)DiaSorin, Inc.2026-06-04
LIAISON® XL MUREX Anti-HDV (318260); LIAISON® XL MUREX Control Anti-HDV (318261) (DEN250032)DiaSorin, Inc.2025-12-23
LIAISON VZV IgG HT, LIAISON Control VZV IgG HT (K231214)DiaSorin, Inc.2023-10-27
LIAISON Anti-HAV; LIAISON XS (K223403)DiaSorin, Inc.2022-12-09
LIAISON Calprotectin, LIAISON Q.S.E.T. Device Plus (K213858)DiaSorin, Inc.2022-07-26
LIAISON MeMed BV, LIAISON MeMed BV Control Set (K213936)DiaSorin, Inc.2022-07-14
LIAISON Ferritin (K193650)DiaSorin, Inc.2021-09-14
LIAISON Lyme IgM, LIAISON Lyme IgM Control Set, LIAISON Lyme Total Antibody Plus (K202573)DiaSorin, Inc.2021-02-18